Radiation therapy for prostate cancer: What’s the best in 2021

2021 ◽  
pp. 039156032110423
Author(s):  
Francesco Cellini ◽  
Luca Tagliaferri ◽  
Vincenzo Frascino ◽  
Anna Rita Alitto ◽  
Bruno Fionda ◽  
...  

Radiotherapy is highly involved in the management of prostate cancer. Its features and potential applications experienced a radical evolution over last decades, as they are associated to the continuous evolution of available technology and current oncological innovations. Some application of radiotherapy like brachytherapy have been recently enriched by innovative features and multidisciplinary dedications. In this report we aim to put some questions regarding the following issues regarding multiple aspects of modern application of radiation oncology: the current application of radiation oncology; the modern role of stereotactic body radiotherapy (SBRT) for both the management of primary lesions and for lymph-nodal recurrence; the management of the oligometastatic presentations; the role of brachytherapy; the aid played by the application of the organ at risk spacer (spacer OAR), fiducial markers, electromagnetic tracking systems and on-line Magnetic Resonance guided radiotherapy (MRgRT), and the role of the new opportunity represented by radiomic analysis.

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Carlos Galvis ◽  
María Caicedo Martinez

The use of liquid biopsies, based on circulating tumor cells and tumoral DNA, provides information on the molecular patterns and genomics of Castrate-Resistant Prostate Cancer. There is evidence on the role of the androgen receptor variant 7 as a prognostic and as a follow-up tool, especially as a follow-up to treatment response and resistance with Enzalutamide and Abiraterone. Little is known about the genomics of Castrate Resistant Prostate Cancer and its relationship to radiation therapy’s sensibility. This is particularly relevant for patients with oligometastatic disease, who could obtain a long control of the disease with radiation. In this narrative review, we summarize the available information on liquid biopsies and Castrate Resistant Prostate Cancer. As radiation oncology evolves towards Genomically Adapted Radiation Dose, the role of liquid biopsies as a possible pre-treatment assessment is a future target. Nonetheless, models have been modeled after other malignancies. This highlights the need for further studies to assess the use of personalized medicine in these patients. Keywords: Radiotherapy; Prostate Cancer; Receptors Androgen; Liquid Biopsy; Precision Medicine;


2014 ◽  
Vol 16 (11) ◽  
pp. 993-999 ◽  
Author(s):  
F. Couñago ◽  
M. Recio ◽  
E. del Cerro ◽  
L. Cerezo ◽  
A. Díaz Gavela ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 108-108
Author(s):  
Rainer Kuefer ◽  
Kathleen Day ◽  
Jonathan Rios-Doria ◽  
Matthias Hofer ◽  
Arul Chinnaiyan ◽  
...  

2020 ◽  
Author(s):  
W Kisel ◽  
S Conrad ◽  
S Füssel ◽  
U Sommer ◽  
GB Baretton ◽  
...  

2018 ◽  
Author(s):  
Vicente Herrero-Aguayo ◽  
Juan M Jimenez-Vacas ◽  
Enrique Gomez-Gomez ◽  
Antonio J Leon-Gonzalez ◽  
Prudencio Saez-Martinez ◽  
...  

2020 ◽  
Vol 28 (3) ◽  
pp. 399-405
Author(s):  
Fabrizio Fontana ◽  
Olga A. Babenko

Aim of this letter is to attract the attention of journal readers to the study of exosomes as an important direction in the development of Oncology, in particular, in the diagnosis and treatment of prostate cancer. Exosomes are produced by tumor cells and regulate proliferation, metastasis, and the development of chemoresistance. Their extraction from biological fluids allows further use of these vesicles as potential biomarkers of prostate cancer. In the future, exosomes can be successfully used in the delivery of drugs and other anti-tumor substances to cancer cells.


Sign in / Sign up

Export Citation Format

Share Document